课题基金 / 基金详情

项目摘要

项目成果

STEVEN ZHENG的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):雷帕霉素的机制或哺乳动物靶标(mTOR)是响应促有丝分裂和营养信号的细胞生长和增殖的中央控制器。mTOR通路在人类癌症中经常被过度激活,导致不受控制的癌症生长。因为癌细胞通常对升高的mTOR信号传导“上瘾”,使得mTOR成为理想的癌症药物靶标。高度特异性的mTOR抑制剂雷帕霉素类似物(rapalogs)是FDA批准的用于晚期肾癌和乳腺癌的抗癌药物。然而,他们的疗效是有限的,缺乏了解什么样的病人是响应rapidly治疗。因此,深入了解mTOR信号通路对基础生物学和肿瘤治疗具有重要意义。在本申请中,我们将研究Rab1刺激细胞生长和癌症的机制,Rab1是我们最近发现的一种新型mTOR激活剂。我们将进一步研究Rab1在乳腺癌病理生物学和靶向治疗中的作用。我们预计,该项目的成功完成将有助于回答一些长期存在的关于细胞调控的问题,并实现个性化的癌症治疗。
英文摘要
DESCRIPTION (provided by applicant): Mechanistic or mammalian target of rapamycin (mTOR) is a central controller of cell growth and proliferation in response to mitogenic and nutrient signals. mTOR pathway is frequently hyper-activated in human cancers, leading to uncontrolled cancer growth. Because cancer cells are often 'addicted' to elevated mTOR signaling, rendering mTOR a desirable cancer drug target. The highly specific mTOR inhibitors rapamycin analogs (rapalogs) are FDA-approved anti-cancer drugs for advanced renal and breast cancers. However, their efficacy is limited by lack of understanding of what patients are responsive to rapalog therapy. Therefore, a detailed understanding of mTOR signaling will is of considerable significance to basic biology and cancer therapy. In this application, we will investigate the mechanism of stimulation of cell growth and cancer by Rab1, a novel mTOR activator we recently identified. We will further study the role of Rab1 in the pathobiology and targeted therapy of breast cancer. We anticipate that successful completion of this project will help answer some long-standing questions on cell regulation and enable individualized cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oncogenic Chromatin Remodeling and Anticancer Mechanisms
Metabolic Control and Anticancer Mechanism
Metabolic Control and Anticancer Mechanism
Metabolic Control and Anticancer Mechanism
海外基金